The National Institute on Aging (NIA) Late Onset of Alzheimer's Disease (LOAD) Family-Based Study (FBS)

美国国家老龄化研究所 (NIA) 晚发型阿尔茨海默病 (LOAD) 基于家庭的研究 (FBS)

基本信息

  • 批准号:
    9358127
  • 负责人:
  • 金额:
    $ 186.27万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2017
  • 资助国家:
    美国
  • 起止时间:
    2017-08-01 至 2022-05-31
  • 项目状态:
    已结题

项目摘要

The National Institute of Aging Late Onset Alzheimer’s Disease Family Based Study (NIA-LOAD FBS) began in 2003, starting a trend of greater cooperation and sharing of clinical and biological resources among researchers. To date, a total of 1,454 multiplex late onset AD (LOAD) families have been recruited with 8,543 family members clinically assessed and DNA sampled. We have also recruited 1,030 controls. Genome-wide SNP arrays have been generated on 5,428 individuals, exome chip genotyping on 1,278 individuals, whole exome sequencing in 1,484 and whole genome in 928 family members and controls. The conversion rate of to LOAD among unaffected relatives in the NIA-LOAD FBS is three-fold higher than would be expected among individuals of similar age (see #67 Bibliography). All of these data have been placed in the public domain in NIAGADS and dbGaP. The NIA-LOAD FBS is widely used in Alzheimer disease genetics with 79 high level publications to support this claim (Bibliography). The NIA-LOAD FBS provides an excellent opportunity to improve our understanding of the clinical and biological impact of genetic variation in the elderly. Phenotypic information is continually updated in these families by regular cognitive evaluations and autopsy at the time of death to confirm the diagnosis of LOAD. We have begun to recruit additional family members with a particular emphasis on the offspring generation. We have been able to bank brain tissue from family members creating one of the largest collections of brain tissues for familial LOAD. We will now expand biological sampling to include RNA and peripheral blood mononuclear cells in selected families. As additional genes and variants are identified, the members of the NIA LOAD Family Study will again play a central role as we explore: What is the impact of these risk and protective variants on disease risk? Are the genetic variants highly penetrant? What is the risk of developing LOAD in offspring? Can the presence of variants be used for stratification of patients into specific subtypes for clinical trials? Can the family data be used to identify novel biomarkers of disease risk, age at onset onset or progression? The NIA-LOAD FBS dataset is uniquely poised to address these clinical and biological questions because of its large size, rigorous ascertainment criteria, standardized clinical assessment and lack of restriction to specific mutations. Our efforts have made it easy and seamless for the genetic data to be shared, allowing even more researchers to obtain the data and samples collected as part of the NIA-LOAD FBS for research studies. This is by far the largest collection of LOAD families available in the world. Virtually every major genetic study of Alzheimer’s disease has included patients and controls from the NIA-LOAD FBS dataset. The availability of dense phenotypic and genetic data will also position the NIA-LOAD FBS in to determine the impact of variants identified in whole genome and whole exome sequencing projects currently underway.
美国国家衰老研究所晚发性阿尔茨海默病家族研究(NIA-LOAD FBS)

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

TATIANA M. FOROUD其他文献

TATIANA M. FOROUD的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('TATIANA M. FOROUD', 18)}}的其他基金

Genetic, Biomarker and Biospecimen Core
遗传、生物标志物和生物样本核心
  • 批准号:
    10475194
  • 财政年份:
    2021
  • 资助金额:
    $ 186.27万
  • 项目类别:
Biospecimen Exchange for Neurological Disorders (BioSEND)
神经系统疾病生物样本交换 (BioSEND)
  • 批准号:
    10289967
  • 财政年份:
    2021
  • 资助金额:
    $ 186.27万
  • 项目类别:
Genetic, Biomarker and Biospecimen Core
遗传、生物标志物和生物样本核心
  • 批准号:
    10666625
  • 财政年份:
    2021
  • 资助金额:
    $ 186.27万
  • 项目类别:
Biospecimen Exchange for Neurological Disorders (BioSEND)
神经系统疾病生物样本交换 (BioSEND)
  • 批准号:
    10448512
  • 财政年份:
    2021
  • 资助金额:
    $ 186.27万
  • 项目类别:
Genetic, Biomarker and Biospecimen Core
遗传、生物标志物和生物样本核心
  • 批准号:
    10264436
  • 财政年份:
    2021
  • 资助金额:
    $ 186.27万
  • 项目类别:
Biospecimen Exchange for Neurological Disorders (BioSEND)
神经系统疾病生物样本交换 (BioSEND)
  • 批准号:
    10674941
  • 财政年份:
    2021
  • 资助金额:
    $ 186.27万
  • 项目类别:
The National Institute on Aging (NIA) Late Onset of Alzheimer's Disease (LOAD) Family-Based Study (FBS)
美国国家老龄化研究所 (NIA) 晚发型阿尔茨海默病 (LOAD) 基于家庭的研究 (FBS)
  • 批准号:
    9812732
  • 财政年份:
    2017
  • 资助金额:
    $ 186.27万
  • 项目类别:
Dissecting the genetic contributions to fetal alcohol spectrum disorders
剖析胎儿酒精谱系障碍的遗传因素
  • 批准号:
    10166731
  • 财政年份:
    2017
  • 资助金额:
    $ 186.27万
  • 项目类别:
The National Institute on Aging (NIA) Late Onset of Alzheimer's Disease (LOAD) Family-Based Study (FBS)
美国国家老龄化研究所 (NIA) 晚发型阿尔茨海默病 (LOAD) 基于家庭的研究 (FBS)
  • 批准号:
    10198718
  • 财政年份:
    2017
  • 资助金额:
    $ 186.27万
  • 项目类别:
Analysis and characterization of a cohort of familial Parkinson's disease exomes
家族性帕金森病外显子组的分析和表征
  • 批准号:
    9113248
  • 财政年份:
    2016
  • 资助金额:
    $ 186.27万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 186.27万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 186.27万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 186.27万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 186.27万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 186.27万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 186.27万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 186.27万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 186.27万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 186.27万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 186.27万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了